Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 834 results for "hcv"

Mahindra makes bold statement with Blazo

Mahindra makes bold statement with Blazo

at 6:11 pm | Mahindra announced the launch of its new HCV truck series, BLAZO with Fuelsmart Technology backed by superior mileage and service guarantee, at the Auto Expo. The BLAZO series includes haulage, tractor trailer and tipper vehicles, ... MotorIndia, 1 day ago
Mahindra launches new HCV truck series, BLAZO, 3 days ago

50 images for hcv

Before It's News, 2 days ago
Monthly Prescribing Reference, 1 week ago
MotorIndia, 1 day ago, 1 week ago
NIHR Clinical Research Network, 1 week ago
Monthly Prescribing Reference, 1 day ago
India Infoline, 4 days ago
Project Inform, 4 days ago
Bidness Etc, 5 days ago
Nasdaq, 1 week ago
European Pharmaceutical Review

Bristol-Myers Squibb's Daklinza receives European approval to treat HCV in three new patient populations

Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza for the treatment of chronic hepatitis C (HCV) in three new patient populations. The expanded label allows for the use of Daklinza in combination with ...
 PharmaBiz1 week ago EC approves Daklinza in three new HCV patient populations  European Pharmaceutical Review1 week ago EC approves Daklinza for the treatment of chronic hepatitis C patients  HospitalHealthcare.com4 days ago

Indian cos ink pact with UN-backed MPP to sell HCV drug

organisation MPP to produce and sell generic daclatasvir in 112 countries. Bristol-Myers Squibb's daclatasvir is a novel direct- acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus (HCV). Generic companies Cipla, Emcure, ...
 Business Standard2 weeks ago
Business Standard

M&HCV industry to see 15-20% growth in FY16: Vinod Dasari, Ashok Leyland

*Password should have 8 to 12 Alphanumeric Characters with one Special Character. Confirm Password I want to create a User ID and have read the terms and conditions for the same Register Now Connect with We encourage visitors to register on IIFL. Registering ...
 India Infoline1 month ago Ashok Leyland November M&HCV sales up by 21%  Business Standard2 months ago Ashok Leyland total sales stood at 8,971 units for Nov'15  India Infoline2 months ago Ashok Leyland's total Jan'16 sales rise 30% yoy to 13,886 units  India Infoline6 days ago
Monthly Prescribing Reference

FDA Hepatitis Update - Approval of Zepatier for treatment of chronic hepatitis C genotypes 1 and 4

, FDA approved ZEPATIER, a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated with or without ribavirin for treatment of chronic HCV ...
 National AIDS Treatment Advocacy Project1 day ago Merck Nabs FDA Approval for Zepatier to Treat HCV Genotypes 1 and 4  FDA News3 days ago WuXi AppTec Congratulates MSD on Receiving FDA Approval of ZEPATIER(TM)  Bio-Medicine4 days ago FDA approves Zepatier for HCV genotypes 1, 4  Orthopedics Today1 week ago
India Infoline

Tata Motors down 3%

Tata Motors continued to witness year-on-year growth in the M&HCV segment in December 2015, with a growth of 2%. Tata Motors Ltd stock was down by 3% at Rs.391. Most Sensex stocks have come crashing down due to a fall in global markets especially China which ...
 India Infoline1 month ago Tata Motors bets big on all-Signa range of M&HCVs  Autocar Professional2 days ago
Pakistan Observer

12 million Pakistani affected by Hepatitis B, C

- Karachi—Around 12 million people are affected with Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) in Pakistan. Hepatitis is an inflammation of the liver. Pakistan is among the worst afflicted nations. One person dies of hepatitis after ...
 Pakistan Observer3 days ago Hepatitis C Infections Highly Prevalent Among West Africans  Med India5 days ago 12m Pakistanis suffer from hepatitis B&C  Daily Times3 days ago Experts cite multiple contacts for hepatitis C virus exposure in Ghana  Medical News Today4 days ago

Diminished HCV replication in HCC [Medical Sciences]

Djamila Harouaka a , Ronald E. Engle a , Kurt Wollenberg b , Giacomo Diaz c , Ashley B. Tice a , Fausto Zamboni d , Sugantha Govindarajan e , Harvey Alter f , 1 , David E. Kleiner g , and Patrizia Farci a , 1 a Hepatic Pathogenesis ...
 PNAS4 days ago

FDA clears Merck's single-tablet HCV combo

The FDA approves Merck's (NYSE: MRK ) once-daily single-tablet combination therapy, Zepatier (elbasvir/grazoprevir), with or without ribavirin, for the treatment of adults with chronic hepatitis C infection (HCV) genotypes 1 and 4. The agency ...
 Seeking Alpha1 week ago FDA action date approaches for Merck's HCV single tablet combo  Seeking Alpha1 week ago
American Banking News - Forex

Merck's HCV med Zepatier could reach $2B in peak sales say analysts

Although, Merck ( MRK +2.4%) is playing catch-up to Gilead Sciences ( GILD -4.9%) and AbbVie ( ABBV -3.2%), analysts say Zepatier (elbasvir/grazoprevir) could still pull in $2B+ in peak sales by 2020, considering the company's likely strategy of ...
 Seeking Alpha1 week ago What We're Reading: Can a State Sue Gilead Over the High Price of Its HCV Drugs?  American Journal of Managed Care1 week ago Atria Investments Raises Position in Gilead Sciences, Inc. (GILD)  WKRB News23 hours ago Boston Advisors Sells 32,518 Shares of AbbVie Inc (ABBV)  American Banking News - Forex1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - hcv
Get updated on latest news & your favorite topics right in your inbox!
More     Less